Between Us Clinic Survey Reveals Urologists’ Top Alternative ED Treatment Recommendations
Between Us Clinic Survey Reveals Urologists' Top ED Treatment Recommendations: Diet, Exercise, and Mindfulness Meditation Lead the Way. FORT LAUDERDALE,...
Pharmaceutical
Expert.ai Wins Duck Creek 2024 Hatch-a-Thon
Expert.ai showcased its innovative AI-powered claims solution at Formation '24 conference in Dallas, where Duck Creek Advisory Board and attendees...
ACTO ACQUIRES 4TH DOWN SOLUTIONS, BRINGING TOGETHER TWO INDUSTRY LEADERS
Strategic Acquisition Adds to ACTO's Organic Customer Growth in Top 50 Pharma KISSIMMEE, Fla., June 11, 2024 /PRNewswire/ - Today...
Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics’ Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer Diagnosis
PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11,...
AxoSim Appoints Alif Saleh as Chief Executive Officer to Drive Market Adoption
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer NEW ORLEANS, June 11, 2024 /PRNewswire/ -- AxoSim, a life...
NTT DATA Acquires Majority Stake in ProvenTech
Strengthening its Pharma/Life Science Expertise and Software Portfolio in India BIELEFELD, Germany and HYDERABAD, India, June 11, 2024 /PRNewswire/ -- NTT...
Benchling Builds Digital Data Foundation Powering Sanofi AI-Driven R&D
Over 30 global teams and 1,500 scientists at Sanofi use Benchling for R&D data capture and analysis SAN FRANCISCO, June...
Uniphar Logistics Backing SkyCell on Their Journey Towards Net-zero.
RALEIGH, NC / ACCESSWIRE / June 11, 2024 / Sky Cell AG, founded in Switzerland, continues paving the way for...
Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or...
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT...
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT;...
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the...
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase...
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
2,300 patients in trial enrolled ahead of schedule12-month follow up period underway, with topline data anticipated in 2H 2025Trial designed...
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose,...
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed...
Candel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical...